预约演示
更新于：2025-07-02
Torsemide
托拉塞米
更新于：2025-07-02
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
59
项与 托拉塞米 相关的临床试验NCT07043634
An Open Label, Randomized, Two-period, Two-sequence, Balanced, Single Dose Crossover Study to Evaluate the Effect of Food on the Bioavailability of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Human Subjects
NCT07015671
Bioavailability and Bioequivalence (BA/BE) Study of Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Subjects
NCT06995144
A Randomized, Two-Period, Two-Arm, Double-Dummy, Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide in Patients With Heart Failure (NEXT-HF)
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,407
项与 托拉塞米 相关的文献（医药）2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-05-30CARDIOLOGY
Torsemide in HFrEF: Revisiting the Role of a Potent Loop Diuretic for Enhanced Outcomes and Renal Safety.
Article
作者: Lee, Wei-Chieh ; Wu, Wen-Shiann
2025-05-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Article
作者: Seifert, Roland ; Schröder, Lennart
Abstract:
For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022. The prescribed defined daily doses (DDD) and the costs per defined daily dose for the 10 medicines were taken from the Arzneiverordnungsreport (AVR) from 1986 to 2023, and the changes in prescribing behavior and their causes were analyzed. The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. There are many different reasons for an increase in prescriptions, such as the introduction of generics, a positive study, or a price reduction. Further reasons for an increase in prescriptions are an extension of the indication or the recall of a competing medicine. A change in guidelines or the increasing treatment of laboratory values without clinical symptoms can also lead to an increase in prescriptions. There are also many different reasons for a drop in prescriptions, such as the generic launch of a competitor medicine or a positive study for a competitor medicine. Other reasons for a drop in prescriptions are a negative study or a discussion about the use of a drug. Sometimes, the reasons for prescription changes are also irrational. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 艱鏇製淵願網獵壓廠壓(鹹艱襯憲簾顧築構簾餘) = 積選艱構網糧願鹽憲鹹 淵鹽糧鑰選觸艱網遞鑰 (鏇鹹獵艱鹽繭鏇觸糧鏇 ) 更多 | - | 2025-05-16 | |||
艱鏇製淵願網獵壓廠壓(鹹艱襯憲簾顧築構簾餘) = 壓顧積獵鑰鹹顧壓構獵 淵鹽糧鑰選觸艱網遞鑰 (鏇鹹獵艱鹽繭鏇觸糧鏇 ) 更多 | |||||||
临床3期 | 47 | (Furosemide) | 網憲窪築鬱觸網廠簾觸 = 蓋顧壓鏇遞鹽遞簾構窪 築鹽衊鹹鏇鹹範築獵餘 (獵鏇顧壓獵壓蓋艱繭廠, 衊醖蓋蓋鹹顧壓獵繭簾 ~ 壓願衊鹽構糧遞夢餘築) 更多 | - | 2024-10-15 | ||
(Torsemide) | 網憲窪築鬱觸網廠簾觸 = 齋齋構構壓衊鹹願顧糧 築鹽衊鹹鏇鹹範築獵餘 (獵鏇顧壓獵壓蓋艱繭廠, 構鏇窪網簾遞壓淵願餘 ~ 願醖夢廠範網獵餘獵願) 更多 | ||||||
临床3期 | 88 | 壓廠醖鬱淵膚製簾醖艱(鏇衊簾糧夢鏇簾衊築糧) = 醖製範淵顧顧積鹹糧遞 衊夢壓鹽構夢構積遞鏇 (獵壓齋繭壓齋鹽顧醖鹽, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
壓廠醖鬱淵膚製簾醖艱(鏇衊簾糧夢鏇簾衊築糧) = 觸鹽鬱獵網餘觸構範壓 衊夢壓鹽構夢構積遞鏇 (獵壓齋繭壓齋鹽顧醖鹽, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 壓遞鹹構憲選憲積繭齋(鏇蓋衊鹹願鹹衊觸鏇鬱) = 願鑰夢廠蓋蓋製鹹齋蓋 鹽顧壓簾網齋選衊窪選 (齋鹽壓鑰觸淵顧廠簾獵 ) 更多 | 不佳 | 2024-05-15 | |||
壓遞鹹構憲選憲積繭齋(鏇蓋衊鹹願鹹衊觸鏇鬱) = 鏇醖鏇鹽獵築範鑰糧襯 鹽顧壓簾網齋選衊窪選 (齋鹽壓鑰觸淵顧廠簾獵 ) 更多 | |||||||
N/A | - | 衊鹹廠鑰構選構鹽鹹鹽(襯顧廠構膚糧鹹顧餘築) = low blood pressure 鏇廠網糧鬱築齋淵鏇壓 (餘淵醖餘範襯網願繭願 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 鑰鏇顧膚鑰鑰積艱醖簾 = 簾積範膚壓糧獵齋築襯 齋艱獵艱衊鬱遞蓋窪遞 (選鹹觸鹽齋願鏇顧鏇醖, 獵夢築鹹顧淵獵獵蓋選 ~ 鑰膚衊夢範範繭壓齋鹽) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 鑰鏇顧膚鑰鑰積艱醖簾 = 餘顧憲憲網艱餘齋壓遞 齋艱獵艱衊鬱遞蓋窪遞 (選鹹觸鹽齋願鏇顧鏇醖, 構網觸網餘構鹹願衊願 ~ 夢衊衊製艱襯構鹽願壓) 更多 | ||||||
N/A | - | 範網壓製壓蓋鏇願壓製(範積簾選鑰觸醖簾襯願) = 糧夢願顧顧築築遞齋鬱 鏇觸醖顧顧齋醖簾鬱廠 (壓膚構鑰範範構鹽築遞 ) | - | 2017-08-29 | |||
範網壓製壓蓋鏇願壓製(範積簾選鑰觸醖簾襯願) = 願積襯淵鹽膚蓋鏇積襯 鏇觸醖顧顧齋醖簾鬱廠 (壓膚構鑰範範構鹽築遞 ) | |||||||
临床1期 | 10 | Torasemide-PR 10 mg | 淵選鹹築膚蓋範蓋積遞(製積憲選餘積衊觸襯積) = 築鏇餘壓鹽糧網鹹鏇構 糧廠壓鬱製蓋淵淵鹽淵 (夢艱襯襯蓋製築衊積餘 ) | - | 2015-08-01 | ||
Furosemide-IR 40 mg | 淵選鹹築膚蓋範蓋積遞(製積憲選餘積衊觸襯積) = 遞積簾艱顧壓範觸選襯 糧廠壓鬱製蓋淵淵鹽淵 (夢艱襯襯蓋製築衊積餘 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用